Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Locus Biosciences

Main focus: New treatments against bacterial infections

Company stage: Clinical

Diseases: Urinary tract infection, other infections

Genome editing tool: CRISPR-Cas3

Funding stage: Private

Location: North Carolina, USA

Website: https://www.locus-bio.com/

Partners: Janssen Pharma

Locus Biosciences is a clinical-stage gene-editing company focused on treating bacterial infectious diseases. The company uses its next generation sequencing-based platform to rapidly identify new bacterial targets and phages. Locus uses CRISPR-Cas3 crPhages as the base of their therapies. The phages are designed using machine learning in order to optimise effectiveness against new bacterial targets.

LOCUS Biosciences, Inc.

Press Releases

Related News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases

Webinar

Your Latest CMN News

CMN Weekly (21 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 21, 2025

Some of the best links we picked up around the internet

Bahrain Reports First Administration of CASGEVY in...

Feb. 19, 2025

The Bahrain Oncology Centre announced a major milestone on Sunday with the successful administration of CASGEVY - the world's only approved therapy...

CRISPR–Csm enables single-molecule RNA imaging in...

CMN Briefs

Feb. 18, 2025

A new technique developed by Jennifer Doudna and colleagues at the University of California, Berkeley, achieves single-molecule resolution imaging of...

CRISPR screen links BAF mutation to premature...

CMN Briefs

Feb. 17, 2025

A genome-wide CRISPR screen in fibroblasts from patients with Néstor-Guillermo Progeria Syndrome (NGPS) identified 43 genes that mitigate multiple...

CMN Weekly (14 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 14, 2025

Some of the best links we picked up around the internet

FDA Grants Dual Designations to Arbor's Gene...

CMN Clinical

Feb. 12, 2025

The FDA has granted orphan drug and rare pediatric disease designations to Arbor Biotechnologies' ABO-101, a gene-editing therapeutic candidate for...